Impact Biomedical (IBO) EBIT Margin (2022 - 2026)

Impact Biomedical (IBO) has reported EBIT Margin for 3 consecutive years, with 23400.0% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT Margin fell 692857.0% year-over-year to 23400.0%; the trailing twelve-month figure through Jun 2026 stood at 14548.57% (up 3724266.0% YoY), and the FY2022 full-year result was 6808.0%, changed N/A from the prior year.
• EBIT Margin improved to 23400.0% in Q2 2026 per IBO's latest filing, from 32700.0% in the prior quarter.
• Across five years, EBIT Margin topped out at 1500.0% in Q2 2022 and bottomed at 32700.0% in Q1 2026.
• Historically, EBIT Margin has averaged 15867.62% across 3 years, with a median of 16471.43% in 2025.
• The widest YoY moves for EBIT Margin: up 692857 bps in 2026, down 692857 bps in 2026.
• Over 3 years, EBIT Margin stood at 1500.0% in 2022, then tumbled by 251 bps to 5266.67% in 2025, then plunged by 344 bps to 23400.0% in 2026.
• According to Business Quant data, EBIT Margin over the past three periods registered 23400.0%, 32700.0%, and 5266.67% for Q2 2026, Q1 2026, and Q3 2025 respectively.